Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hyaluronan May Hold Promise for IBD

J Histochem Cytochem; ePub 2017 Dec 1; Kessler et al.

Publish date:: January 11, 2018

Hyaluronan has therapeutic potential to help protect patients from bacterially induced colitis, suggests a new study. Details include:

Human-milk derived hyaluronan has antimicrobial properties that have been shown to protect against Salmonella Typhimurium infection of epithelial cells.
Researchers found that 35 kilodalton hyaluronan (HA35) also has antimicrobial properties, expresses beta-defensin, and disrupts murine Citrobacter rodentium infection.
HA35 has also been shown to destroy murine Salmonella Typhimurium infection and downregulate leaky junction protein claudin-2 expression.

Citation:

Kessler SP, Obery DR, Nickerson KP, et al. Multifunctional role of 35 kilodalton hyaluronan in promoting defense of the intestinal epithelium. [Published online ahead of print December 1, 2017]. J Histochem Cytochem. doi:10.1369/0022155417746775.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Endoscopic intragastric balloon improved NASH parameters,

Autologous fecal microbiota transplantation helped maintain weight loss after ‘green’ Mediterranean diet,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,

Must Reads in IBD & Intestinal Disorders

Normal gut colonizer induces serotonergic system, appears to regulate behavior,

IL-23 plays key roles in antimicrobial macrophage activity,

Diarrhea prevalent among COVID-19 patients with IBD,

Complete endoscopic healing tied to better Crohn’s disease outcomes,

Studies eyes risks for poor outcomes in primary sclerosing cholangitis,